Calidi Biotherapeutics, Inc.
CLDI
$0.415
-$0.016-3.71%
AMEX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -28.05% | -14.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.96% | -9.46% | |||
| Operating Income | 22.96% | 9.46% | |||
| Income Before Tax | 18.24% | 11.96% | |||
| Income Tax Expenses | 400.00% | -112.50% | |||
| Earnings from Continuing Operations | 18.17% | 12.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 240.00% | -- | |||
| Net Income | 18.94% | 12.36% | |||
| EBIT | 22.96% | 9.46% | |||
| EBITDA | 23.34% | 9.66% | |||
| EPS Basic | 58.51% | 53.72% | |||
| Normalized Basic EPS | 58.79% | 40.33% | |||
| EPS Diluted | 58.51% | 53.72% | |||
| Normalized Diluted EPS | 58.79% | 40.33% | |||
| Average Basic Shares Outstanding | 95.41% | 46.85% | |||
| Average Diluted Shares Outstanding | 95.41% | 46.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||